Nyxoah Genio Wins Prix Galien UK 2026 Award for Best Medical Technology
Summary
Nyxoah SA announced that its Genio hypoglossal nerve stimulation therapy for obstructive sleep apnea was awarded the Prix Galien UK 2026 Award for Best Medical Technology. The Prix Galien is widely regarded as one of the highest honors in healthcare innovation. The award recognizes Genio's contribution to treating OSA, a chronic condition affecting millions of people and associated with increased risks of cardiovascular disease, metabolic disorders, and impaired quality of life.
Why it matters
This prestigious award validates Genio's clinical and technological differentiation in the competitive sleep apnea neurostimulation market. Following FDA approval in August 2025 and the U.S. commercial launch, this recognition supports Nyxoah's position as it accelerates American market expansion and continues to grow adoption across Europe and international markets.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial